Vesiclemia: counting on extracellular vesicles for glioblastoma patients

Although rare, glioblastoma is a devastating tumor of the central nervous system characterized by a poor survival and an extremely dark prognosis, making its diagnosis, treatment, and monitoring highly challenging. Numerous studies have highlighted extracellular vesicles (EVs) as key players of tumo...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2020-09, Vol.39 (38), p.6043-6052
Main Authors: Sabbagh, Quentin, Andre-Gregoire, Gwennan, Guevel, Laetitia, Gavard, Julie
Format: Article
Language:English
Subjects:
Animals
Biological Transport
Biomarkers, Tumor
Body fluids
Brain cancer
Brain Neoplasms - blood
Brain Neoplasms - diagnosis
Brain Neoplasms - genetics
Brain Neoplasms - metabolism
Brain tumors
Cell Communication
Cell Fractionation - methods
Central nervous system
Cerebrospinal fluid
Development and progression
Diagnosis
Disease Management
Disease Progression
Extracellular vesicles
Extracellular Vesicles - metabolism
Glioblastoma
Glioblastoma - blood
Glioblastoma - diagnosis
Glioblastoma - genetics
Glioblastoma - metabolism
Glioblastoma multiforme
Humans
Invasiveness
Life Sciences
Medical prognosis
Molecular Diagnostic Techniques
Paracrine signalling
Patients
Prognosis
Tumor Microenvironment - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although rare, glioblastoma is a devastating tumor of the central nervous system characterized by a poor survival and an extremely dark prognosis, making its diagnosis, treatment, and monitoring highly challenging. Numerous studies have highlighted extracellular vesicles (EVs) as key players of tumor growth, invasiveness, and resistance, as they carry oncogenic material. Moreover, EVs have been shown to communicate locally in a paracrine way but also at remote throughout the organism. Indeed, recent reports demonstrated the presence of brain tumor-derived EVs into body fluids such as plasma and cerebrospinal fluid. Fluid-associated EVs have indeed been suspected to reflect quantitative and qualitative information about the status and fate of the tumor and can potentially act as a resource for noninvasive biomarkers that might assist in diagnosis, treatment, and follow-up of glioblastoma patients. Here, we coined the name vesiclemia to define the concentration of plasmatic EVs, an intuitive term to be directly transposed in the clinical jargon.
ISSN:0950-9232
1476-5594
DOI:10.1038/s41388-020-01420-x